Your browser doesn't support javascript.
Pathogenesis and Management of COVID-19.
Alfarouk, Khalid O; AlHoufie, Sari T S; Ahmed, Samrein B M; Shabana, Mona; Ahmed, Ahmed; Alqahtani, Saad S; Alqahtani, Ali S; Alqahtani, Ali M; Ramadan, AbdelRahman M; Ahmed, Mohamed E; Ali, Heyam S; Bashir, Adil; Devesa, Jesus; Cardone, Rosa A; Ibrahim, Muntaser E; Schwartz, Laurent; Reshkin, Stephan J.
  • Alfarouk KO; Hala Alfarouk Cancer Center, Department of Evolutionary Pharmacology and Tumor Metabolism, Khartoum 11123, Sudan.
  • AlHoufie STS; Research Center, Zamzam University College, Khartoum 11123, Sudan.
  • Ahmed SBM; Medical Laboratories Technology Department, College of Applied Medical Sciences, Taibah University, Medina 42353, Saudi Arabia.
  • Shabana M; College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
  • Ahmed A; Pharmacology Department, Faculty of Medicine, Fayoum University, Fayoum 63514, Egypt.
  • Alqahtani SS; Department of Oesphogastric and General Surgery, University Hospitals of Leicester, Leicester LE5 4PW, UK.
  • Alqahtani AS; Pharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
  • Alqahtani AM; Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Najran University, Najran 66446, Saudi Arabia.
  • Ramadan AM; Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
  • Ahmed ME; Department of Preventive Dental Sciences, Ibn Sina National College, Jeddah 22421, Saudi Arabia.
  • Ali HS; Research Center, Zamzam University College, Khartoum 11123, Sudan.
  • Bashir A; Department of Surgery, Faculty of Medicine Al-Neelain University, Khartoum 11111, Sudan.
  • Devesa J; Faculty of Pharmacy, University of Khartoum, P. O. Box 321, Khartoum 11111, Sudan.
  • Cardone RA; Hala Alfarouk Cancer Center, Department of Evolutionary Pharmacology and Tumor Metabolism, Khartoum 11123, Sudan.
  • Ibrahim ME; Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan.
  • Schwartz L; Scientific Direction, Foltra Medical Centre, 15886 Teo, Spain.
  • Reshkin SJ; Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, 70126 Bari, Italy.
J Xenobiot ; 11(2): 77-93, 2021 May 21.
Article in English | MEDLINE | ID: covidwho-2248928
ABSTRACT
COVID-19, occurring due to SARS-COV-2 infection, is the most recent pandemic disease that has led to three million deaths at the time of writing. A great deal of effort has been directed towards altering the virus trajectory and/or managing the interactions of the virus with its subsequent targets in the human body; these interactions can lead to a chain reaction-like state manifested by a cytokine storm and progress to multiple organ failure. During cytokine storms the ratio of pro-inflammatory to anti-inflammatory mediators is generally increased, which contributes to the instigation of hyper-inflammation and confers advantages to the virus. Because cytokine expression patterns fluctuate from one person to another and even within the same person from one time to another, we suggest a road map of COVID-19 management using an individual approach instead of focusing on the blockbuster process (one treatment for most people, if not all). Here, we highlight the biology of the virus, study the interaction between the virus and humans, and present potential pharmacological and non-pharmacological modulators that might contribute to the global war against SARS-COV-2. We suggest an algorithmic roadmap to manage COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: J Xenobiot Year: 2021 Document Type: Article Affiliation country: Jox11020006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: J Xenobiot Year: 2021 Document Type: Article Affiliation country: Jox11020006